Form 4: Boston Scientific EVP Sells Shares After Option Exercise
Statement of Changes in Beneficial Ownership
Joseph Michael Fitzgerald, EVP & Group President of Cardiology at Boston Scientific, sold 50,000 shares of common stock for over $98 per share after exercising options at $26.15, pursuant to a Rule 10b5-1 plan.
Summary
- Joseph Michael Fitzgerald, Executive Vice President & Group President, Cardiology, at Boston Scientific Corp (BSX), reported transactions on October 1, 2025.
- Exercised stock options to acquire 50,000 shares of common stock at an exercise price of $26.15 per share.
- Subsequently sold 8,245 shares of common stock at a weighted average price of $98.9063 per share.
- Sold an additional 41,755 shares of common stock at a weighted average price of $98.3797 per share.
- All reported transactions were executed pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025.
- Following these transactions, Fitzgerald directly owns 178,342 shares of common stock and 50,000 stock options.
- An additional 5,234 shares are indirectly owned by a child, for which beneficial ownership is disclaimed by Fitzgerald.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. While insider selling can be a negative signal, these transactions were pre-planned under a Rule 10b5-1 plan, mitigating concerns about opportunistic selling. The significant profit realized by the insider also reflects positively on the company's stock performance leading up to the sale.
Positives
- EVP Fitzgerald realized a significant profit by exercising options at $26.15 and selling the acquired shares at an average price of approximately $98.64.
- The transactions were conducted under a pre-established Rule 10b5-1 trading plan, indicating a planned sale rather than a reaction to new, non-public information, which can mitigate negative market perception.
Negatives
- Insider selling, even if pre-planned, reduces the insider's direct equity stake in the company, which can sometimes be perceived negatively by the market.
Risks
- No specific risks to the company's operations or financial health are mentioned in this Form 4 filing.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Management Comments
- The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose.
Industry Context
This Form 4 filing details an insider transaction and does not provide information relevant to broader industry trends or competitor analysis.
Stakeholder Impact
- Shareholders may note the insider's decision to monetize a portion of their equity holdings, which was pre-planned and reflects a significant gain on options.
Key Dates
| Date | Description |
|---|---|
| 2018-12-01 | First anniversary of the option grant date, marking the beginning of four equal annual vesting installments for the stock options. |
| 2025-02-27 | Adoption date of the Rule 10b5-1 trading plan under which the transactions were effected. |
| 2025-10-01 | Date of the stock option exercise and subsequent share sales. |
| 2027-12-01 | Expiration date of the stock options. |
Keywords
Boston Scientific, BSX, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Joseph Michael Fitzgerald, Rule 10b5-1, Cardiology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.